Drug intelligence / Profile preview

192IgG-saporin

Development stage
Preclinical
Lead developer
Advanced Targeting Systems
Modality
Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intracerebroventricular, Intracerebral, Intraseptal (preclinical, Research Use Only)
01

Overview

192IgG-saporin is a chemically conjugated **antibody-drug conjugate** consisting of the mouse monoclonal antibody 192-IgG and the ribosome-inactivating protein **saporin**. The 192-IgG binds specifically to the rat low-affinity neurotrophin receptor (p75), richly expressed on cholinergic neurons in the basal forebrain. When administered intracerebroventricularly or locally in rat brain, this immunotoxin is selectively internalized by p75-expressing cholinergic neurons, resulting in highly specific and permanent ablation of these neurons through the ribosome-inactivating action of saporin. This selective neurotoxin is commonly used as a research tool to model **Alzheimer's disease–associated cholinergic deficits**, study basal forebrain cholinergic system functions, and evaluate mechanisms of neurodegeneration and neuroprotection. Its action leads to depletion of cholinergic neurons in the medial septum, diagonal band of Broca, and nucleus basalis of Meynert, impairing memory and cognition in animal models[1][3][5][6][9].

Other names
192IgG-saporin192-IgG-SAP192IgG-SAP
02

Targets

NGFR (p75NTR)

Beyond the preview

Go deeper on 192IgG-saporin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 192IgG-saporin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call